Joel Rosenberg, MD
Cardiovascular Disease · Washington, DCNPI 1215951181
Payments from drug & device makers
Across 6 payments — averaging $37.92 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Actelion Pharmaceuticals US, Inc.$100
- Amgen$75
- Innovation Technologies Inc$39
- ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$14
What the payments were for
- Food & beverage$228100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Actelion Pharmaceuticals US, Inc. | 1 | $100 |
| Amgen | 3 | $75 |
| Innovation Technologies Inc | 1 | $39 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 1 | $14 |
How this compares
$228 in reported general payments places this provider in the 25th percentile of 105 cardiovascular disease providers in District of Columbia.
See all cardiovascular disease providers in District of Columbia →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 221 | $304,558 |
| Repatha SureclickEvolocumab | 141 | $128,452 |
| JardianceEmpagliflozin | 43 | $68,775 |
| EntrestoSacubitril/Valsartan | 44 | $61,325 |
| XareltoRivaroxaban | 51 | $53,913 |
| Praluent PenAlirocumab | 27 | $26,741 |
| Rosuvastatin Calcium | 453 | $11,618 |
| Ezetimibe | 325 | $10,876 |
| Diltiazem 24hr Er (La)Diltiazem Hcl | 55 | $7,833 |
| BrilintaTicagrelor | 13 | $7,823 |
| Metoprolol Succinate | 478 | $7,502 |
| Atorvastatin Calcium | 410 | $6,392 |
| Telmisartan | 101 | $4,623 |
| Valsartan | 68 | $3,793 |
| Candesartan Cilexetil | 35 | $3,741 |
Paid to pharmacies, not to this prescriber.
Other cardiovascular disease in Washington
- Felton AndersonWashington$2.3M
- Neil WeissmanWashington$1.9M
- Mardi Gomberg-MaitlandWashington$1.1M
- Hayder HashimWashington$989K
- Joshua YamamotoWashington$376K
- Jaffar KhanWashington$330K
- Susan O'DonoghueWashington$207K
- Richard KatzWashington$207K
- Isaac Opoku-AsareWashington$146K
- Zuyue WangWashington$143K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.